Semaglutide

Semaglutide is among the most extensively studied incretin therapies. In branded injectable forms it is indicated, under clinician supervision, to improve glycemic control in adults with type 2 diabetes (e.g., Ozempic® pathway) and for chronic weight management in adults with obesity or overweight plus weight-related comorbidity, with cardiovascular risk-reduction labeling on certain products (e.g., Wegovy® pathway). Additional labeled uses may include MASH with fibrosis under accelerated pathways where approved. LIRAVEXIN catalogs lyophilized bulk strengths for compounding/clinic pathways—not consumer DIY use. Clinicians select the indication, product presentation, and titration based on the patient’s metabolic profile, GI tolerability, and concomitant medicines (insulin, sulfonylureas, other incretins). Coadministration with other GLP-1 receptor agonists is generally not recommended on labels.

Typical labeled SC ranges: Ozempic-class glycemic pathway 0.25 mg → 0.5 mg → 1 mg → up to 2 mg once weekly; Wegovy-class weight pathway 0.25 → 0.5 → 1 → 1.7 → maintenance 2.4 mg (or 1.7 mg) once weekly. Exact regimen is product- and indication-specific.

Once weekly subcutaneous injection on the same day each week (any time of day, with or without meals per label).

Subcutaneous (abdomen, thigh, or upper arm); rotate sites.